Asensus Surgical, Inc. – AMEX:ASXC
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
Asensus Surgical stock price monthly change
+2.57%
month
Asensus Surgical stock price quarterly change
+25.56%
quarter
Asensus Surgical stock price yearly change
-34.81%
year
Asensus Surgical key metrics
Market Cap | 94.92M |
Enterprise value | 159.85M |
P/E | -2.06 |
EV/Sales | 22.55 |
EV/EBITDA | -2.50 |
Price/Sales | 22.66 |
Price/Book | 1.61 |
PEG ratio | 0.14 |
EPS | -0.30 |
Revenue | 8.72M |
EBITDA | -70.84M |
Income | -78.71M |
Revenue Q/Q | 15.06% |
Revenue Y/Y | 24.68% |
Profit margin | -1066.19% |
Oper. margin | -1063.4% |
Gross margin | -53.41% |
EBIT margin | -1063.4% |
EBITDA margin | -812.08% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAsensus Surgical stock price history
Asensus Surgical stock forecast
Asensus Surgical financial statements
| Jun 2023 | 1.08M | -20.66M | -1911.38% |
|---|---|---|---|
| Sep 2023 | 1.08M | -18.31M | -1682.09% |
| Dec 2023 | 5.43M | -17.23M | -317.34% |
| Mar 2024 | 1.12M | -22.49M | -2003.29% |
| Mar 2024 | 1.12M | -22.49M | -2003.29% |
|---|---|---|---|
| Sep 2025 | 7.8M | -7.93M | -101.67% |
| Oct 2025 | 7.8M | -8.07M | -103.56% |
| Dec 2025 | 8.3M | -8.07M | -97.32% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 0.92% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 78371000 | 16.86M | 21.52% |
|---|---|---|---|
| Sep 2023 | 70727000 | 23.47M | 33.19% |
| Dec 2023 | 60534000 | 27.12M | 44.8% |
| Mar 2024 | 40814000 | 27.79M | 68.09% |
| Jun 2023 | -17.95M | 6.56M | 194K |
|---|---|---|---|
| Sep 2023 | -15.04M | 20.77M | 9.74M |
| Dec 2023 | -13.37M | 7.42M | 172K |
| Mar 2024 | -14.00M | 3M | 811K |
Asensus Surgical alternative data
| Aug 2023 | 183 |
|---|---|
| Sep 2023 | 183 |
| Oct 2023 | 183 |
| Nov 2023 | 183 |
| Dec 2023 | 183 |
| Jan 2024 | 183 |
| Feb 2024 | 183 |
| Mar 2024 | 207 |
| Apr 2024 | 207 |
| May 2024 | 207 |
| Jun 2024 | 207 |
| Jul 2024 | 207 |
Asensus Surgical other data
6.96%
-18.94%
of ASXC is owned by hedge funds
51
-13
6.78M
-18.47M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 586154 | 0 |
| Dec 2023 | 18134 | 18134 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SHAMEZE RAMPERTAB officer: EVP, Chief Financial O.. | Common Stock | 81,521 | N/A | N/A | ||
Option | SHAMEZE RAMPERTAB officer: EVP, Chief Financial O.. | Restricted Stock Units | 81,521 | N/A | N/A | ||
Option | FERNANDO ANTHONY C. J. director, officer.. | Common Stock | 271,739 | N/A | N/A | ||
Option | FERNANDO ANTHONY C. J. director, officer.. | Restricted Stock Units | 271,739 | N/A | N/A | ||
Option | SHAMEZE RAMPERTAB officer: EVP, Chief Financial O.. | Common Stock | 280,909 | N/A | N/A | ||
Option | SHAMEZE RAMPERTAB officer: EVP, Chief Financial O.. | Restricted Stock Units | 58,333 | N/A | N/A | ||
Option | SHAMEZE RAMPERTAB officer: EVP, Chief Financial O.. | Restricted Stock Units | 58,334 | N/A | N/A | ||
Option | SHAMEZE RAMPERTAB officer: EVP, Chief Financial O.. | Restricted Stock Units | 62,417 | N/A | N/A | ||
Option | SHAMEZE RAMPERTAB officer: EVP, Chief Financial O.. | Restricted Stock Units | 19,704 | N/A | N/A | ||
Option | FERNANDO ANTHONY C. J. director, officer.. | Common Stock | 1,042,772 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Anthony Fernando (1972) Pres, Chief Executive Officer & Director | $1,410,000 |
Mr. Shameze Rampertab B.Sc. MBA, CA, CPA (1967) Executive Vice President & Chief Financial Officer | $179,550 |
-
When is Asensus Surgical's next earnings date?
Unfortunately, Asensus Surgical's (ASXC) next earnings date is currently unknown.
-
Does Asensus Surgical pay dividends?
No, Asensus Surgical does not pay dividends.
-
How much money does Asensus Surgical make?
Asensus Surgical has a market capitalization of 94.92M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.02% to 8.58M US dollars.
-
What is Asensus Surgical's stock symbol?
Asensus Surgical, Inc. is traded on the AMEX under the ticker symbol "ASXC".
-
What is Asensus Surgical's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Asensus Surgical?
Shares of Asensus Surgical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Asensus Surgical's key executives?
Asensus Surgical's management team includes the following people:
- Mr. Anthony Fernando Pres, Chief Executive Officer & Director(age: 53, pay: $1,410,000)
- Mr. Shameze Rampertab B.Sc. MBA, CA, CPA Executive Vice President & Chief Financial Officer(age: 58, pay: $179,550)
-
How many employees does Asensus Surgical have?
As Jul 2024, Asensus Surgical employs 207 workers.
-
When Asensus Surgical went public?
Asensus Surgical, Inc. is publicly traded company for more then 34 years since IPO on 6 Aug 1991.
-
What is Asensus Surgical's official website?
The official website for Asensus Surgical is asensus.com.
-
Where are Asensus Surgical's headquarters?
Asensus Surgical is headquartered at 1 TW Alexander Drive, Durham, NC.
-
How can i contact Asensus Surgical?
Asensus Surgical's mailing address is 1 TW Alexander Drive, Durham, NC and company can be reached via phone at +91 97658400.
Asensus Surgical company profile:
Asensus Surgical, Inc.
asensus.comExchange:
AMEX
Full time employees:
207
Industry:
Medical - Devices
Sector:
Healthcare
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
1 TW Alexander Drive
Durham, NC 27703
Durham, NC 27703
CIK: 0000876378
ISIN: US04367G1031
CUSIP: 04367G103
